Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acute Poisonings from Synthetic Cannabinoids — 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010–2015
Anne M. Riederer, Sharan Campleman, Robert G. Carlson, et al.
MMWR Morbidity and Mortality Weekly Report (2016) Vol. 65, Iss. 27, pp. 692-695
Open Access | Times Cited: 89

Showing 1-25 of 89 citing articles:

The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review
Vera L. Alves, João Gonçalves, Joselin Aguiar, et al.
Critical Reviews in Toxicology (2020) Vol. 50, Iss. 5, pp. 359-382
Closed Access | Times Cited: 153
Focus on cannabinoids and synthetic cannabinoids
Reynald Le Boisselier, João Alexandre, Véronique Lelong‐Boulouard, et al.
Clinical Pharmacology & Therapeutics (2016) Vol. 101, Iss. 2, pp. 220-229
Closed Access | Times Cited: 149
Pharmacological evaluation of new constituents of “Spice”: synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds
Clara T. Schoeder, Cornelius Heß, Burkhard Madea, et al.
Forensic Toxicology (2018) Vol. 36, Iss. 2, pp. 385-403
Open Access | Times Cited: 106
Synthetic Cannabinoids: A Pharmacological and Toxicological Overview
Rita Roque Bravo, Rafaela Sofia Silva, R.F. Malheiro, et al.
The Annual Review of Pharmacology and Toxicology (2022) Vol. 63, Iss. 1, pp. 187-209
Open Access | Times Cited: 46
Psychosis and synthetic cannabinoids
Huiqiong Deng, Christopher D. Verrico, Thomas R. Kosten, et al.
Psychiatry Research (2018) Vol. 268, pp. 400-412
Closed Access | Times Cited: 60
Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists
Marie H. Deventer, Katleen Van Uytfanghe, Inge M. J. Vinckier, et al.
Drug Testing and Analysis (2022) Vol. 14, Iss. 9, pp. 1565-1575
Open Access | Times Cited: 30
Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: A case series and review of the literature
Patil Armenian, Michael A. Darracq, Jirair Gevorkyan, et al.
Neuropharmacology (2017) Vol. 134, pp. 82-91
Closed Access | Times Cited: 55
Notes from the Field: Outbreak of Severe Illness Linked to the Vitamin K Antagonist Brodifacoum and Use of Synthetic Cannabinoids — Illinois, March–April 2018
Erin D. Moritz, Connie Austin, Michael Wahl, et al.
MMWR Morbidity and Mortality Weekly Report (2018) Vol. 67, Iss. 21, pp. 607-608
Open Access | Times Cited: 52
The Association Between Past 12-Month Synthetic Cannabinoid Polysubstance Use and Cannabis Use Disorder in a Nationally Representative US Sample
Weisiyu Qin, Dong‐Chul Seo, Shin Hyung Lee, et al.
International Journal of Mental Health and Addiction (2025)
Closed Access
The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report)
Vincenzo Abbate, Michael Schwenk, Brandon C. Presley, et al.
Pure and Applied Chemistry (2018) Vol. 90, Iss. 8, pp. 1255-1282
Open Access | Times Cited: 44
Health Risk Behaviors With Synthetic Cannabinoids Versus Marijuana
Heather B. Clayton, Richard Lowry, Carmen Ashley, et al.
PEDIATRICS (2017) Vol. 139, Iss. 4
Open Access | Times Cited: 43
Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003–2017: part 3 – spatiotemporal, multivariable and causal inferential pathfinding and exploratory analyses of prostate and ovarian cancers
Albert Stuart Reece, Gary Kenneth Hulse
Archives of Public Health (2022) Vol. 80, Iss. 1
Open Access | Times Cited: 22
Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003–2017: part 1 – continuous bivariate analysis
Albert Stuart Reece, Gary Kenneth Hulse
Archives of Public Health (2022) Vol. 80, Iss. 1
Open Access | Times Cited: 21
Diverse psychotropic substances detected in drug and drug administration equipment samples submitted to drug checking services in Toronto, Ontario, Canada, October 2019–April 2020
Kristy Scarfone, Nazlee Maghsoudi, Karen McDonald, et al.
Harm Reduction Journal (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 20
A new cannabinoid receptor 1 selective agonist evading the 2021 “China ban”: ADB‐FUBIATA
Marie H. Deventer, Katleen Van Uytfanghe, Inge M. J. Vinckier, et al.
Drug Testing and Analysis (2022) Vol. 14, Iss. 9, pp. 1639-1644
Open Access | Times Cited: 20
Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003–2017: part 2 – categorical bivariate analysis and attributable fractions
Albert Stuart Reece, Gary Kenneth Hulse
Archives of Public Health (2022) Vol. 80, Iss. 1
Open Access | Times Cited: 19
Increases in synthetic cannabinoids-related harms: Results from a longitudinal web-based content analysis
François Lamy, Raminta Daniulaityte, Ramzi W. Nahhas, et al.
International Journal of Drug Policy (2017) Vol. 44, pp. 121-129
Open Access | Times Cited: 37
Synthetic Cannabinoid Use Among High School Seniors
Joseph J. Palamar, Monica J. Barratt, Leigh Coney, et al.
PEDIATRICS (2017) Vol. 140, Iss. 4
Open Access | Times Cited: 37
Systematic review of nephrotoxicity of drugs of abuse, 2005–2016
Kanaan Mansoor, Murad Kheetan, Saba Shahnawaz, et al.
BMC Nephrology (2017) Vol. 18, Iss. 1
Open Access | Times Cited: 37
Notes from the Field: Acute Poisonings from a Synthetic Cannabinoid Sold as Cannabidiol — Utah, 2017–2018
Roberta Horth, Barbara Insley Crouch, B. Zane Horowitz, et al.
MMWR Morbidity and Mortality Weekly Report (2018) Vol. 67, Iss. 20, pp. 587-588
Open Access | Times Cited: 32
Synthetic Cannabinoid‐Associated Multiple Organ Failure: Case Series and Literature Review
Faith Armstrong, Michael T. McCurdy, Mojdeh S. Heavner
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2019) Vol. 39, Iss. 4, pp. 508-513
Open Access | Times Cited: 31
The Toxicology Investigators Consortium Case Registry—the 2016 Experience
Lynn A. Farrugia, Sean H. Rhyee, Diane P. Calello, et al.
Journal of Medical Toxicology (2017) Vol. 13, Iss. 3, pp. 203-226
Open Access | Times Cited: 31
Lifetime prevalence of novel psychoactive substances use among adults in the USA: Sociodemographic, mental health and illicit drug use correlates. Evidence from a population-based survey 2007–2014
Jessica Neicun, Justin Yang, Hueyjong Shih, et al.
PLoS ONE (2020) Vol. 15, Iss. 10, pp. e0241056-e0241056
Open Access | Times Cited: 26
Neuropsychiatric Sequelae in Adolescents With Acute Synthetic Cannabinoid Toxicity
Sarah Anderson, Anna M. Oprescu, Diane P. Calello, et al.
PEDIATRICS (2019) Vol. 144, Iss. 2
Open Access | Times Cited: 24
Synthetic Cannabinoids-"Spice" Can Induce a Psychosis: A Brief Review.
Rajashekar Reddy Yeruva, Hema Madhuri Mekala, Meesha Sidhu, et al.
PubMed (2019) Vol. 16, Iss. 1-2, pp. 31-32
Closed Access | Times Cited: 24
Page 1 - Next Page

Scroll to top